Vaccine escape challenges virus prevention: The example of two vaccine‐preventable oncogenic viruses
Open Access
- 9 November 2023
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (11) , e29184
Abstract
Over the years, the pace of developing vaccines for HBV and HPV has never stopped. After more than 30 years of application, the HBV vaccine has reduced 80% of hepatocellular carcinoma (HCC). However, vaccine escape variants occur under selective pressure induced by widespread vaccination and antiviral therapy, which results in fulminant infection and horizontal transmission. Several mechanisms have been studied to explain HBV vaccine escape, including vaccine escape mutations (VEMs) in the major hydrophilic region, which leads to a decrease in the binding ability to neutralize antibodies and is the primary escape mechanism, protein conformational and N‐linked glycosylation sites changes caused by VEMs, differences in genotype distribution, gene recombination, and some temporarily unknown reasons. However, effective solutions are still being explored. The HPV vaccine has also been proven to prevent 70%–90% of cervical cancer worldwide. Cases of HPV infection after being vaccinated have been observed in clinical practice. However, few researchers have paid attention to the mechanism of HPV vaccine escape. Thus, we reviewed the literature on vaccine escape of both HBV and HPV to discuss the mechanism of the virus escaping from vaccine protection and possible solutions to this problem. We analyzed the gap between studies of HPV and HBV and made prospects for further research in HPV vaccine escape.Keywords
This publication has 132 references indexed in Scilit:
- Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16Oncogene, 2013
- The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancerBritish Journal of Cancer, 2012
- A Pan-HPV Vaccine Based on Bacteriophage PP7 VLPs Displaying Broadly Cross-Neutralizing Epitopes from the HPV Minor Capsid Protein, L2PLOS ONE, 2011
- Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in MalesNew England Journal of Medicine, 2011
- Impairment of Hepatitis B Virus Virion Secretion by Single-Amino-Acid Substitutions in the Small Envelope Protein and Rescue by a Novel Glycosylation SiteJournal of Virology, 2010
- A deletion and point mutation study of the human papillomavirus type 16 major capsid geneVirus Research, 2006
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI: Journal of the National Cancer Institute, 2005
- Against which human papillomavirus types shall we vaccinate and screen? the international perspectiveInternational Journal of Cancer, 2004
- Sequence variation in the L1 gene of human papillomavirus type 16 from AfricaArchives of Virology, 1995
- Gly145 to Arg substitution in HBs antigen of immune escape mutant of hepatitis B virusBiochemical and Biophysical Research Communications, 1992